Aflibercept submitted for fourth indication in EU

Article

Bayer HealthCare has applied to the EMA for marketing authorization of aflibercept solution for injection for the treatment of patients with visual impairment caused by macular oedema secondary to BRVO.

Bayer HealthCare has applied to the European Medicines Agency (EMA) for marketing authorization of aflibercept solution for injection (EYLEA) for the treatment of patients with visual impairment caused by macular oedema secondary to branch retinal vein occlusion (BRVO).

Aflibercept solution for injection into the eye is approved for the treatment of patients with neovascular age-related macular degeneration and the treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion. Bayer has previously filed for marketing authorization for the treatment of diabetic macular oedema (DME).

The EMA submission is based on the positive results from the Phase 3 VIBRANT trial, a double-masked, randomized, active-controlled study of patients with macular oedema secondary to BRVO. In the VIBRANT study, 53% of patients who received aflibercept solution for injection 2 mg monthly gained at least 15 letters (equivalent to three lines) in best corrected visual acuity (BCVA) from baseline at week 24, compared to 27% of patients who received laser. In addition, the patients who received aflibercept solution for injection achieved a 17.0 letter mean improvement over baseline in BCVA compared to a 6.9 letter mean improvement in patients who received laser.

Aflibercept solution for injection into the eye has been approved in more than 70 countries for the treatment of patients with neovascular age-related macular degeneration and nearly 60 countries for the treatment of visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO).

Regulatory submissions have been made in Europe, Japan, Asia Pacific, Latin America and the US for the treatment of diabetic macular oedema (DME), and for BRVO in the US. Approval is being sought in Japan and Asia Pacific, for the treatment of choroidal neovascularization secondary to pathologic myopia (myopic CNV).

For more details visit the company's website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.